Genentech

ACTEMRA

Manufacturer:

Genentech

Actemra HCPCS:

Q0249

HCPCS Code Descriptor:

Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg

Category:

Q Code

Actemra NDCs:

50242-0143-01, 50242-0138-01, 50242-0136-01, 50242-0137-01, 50242-0135-01

Primary Type:

COVID-19

Generic/Specialty Status:

Single-Source

Package Type:

Not Found

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team has identified potential listing errors/discrepancies with the following NDCs:

50242-0136-01, 50242-0137-01, 50242-0135-01

About Actemra:

ACTEMRA is a COVID-19 drug manufactured by Genentech and administered via the Intravenous route of administration. The Q Code: Q0249 is aligned to the drug ACTEMRA.

ACCESS PRICING AND MORE BY REGISTERING

Q0249 Added Date:

June 24, 2021

Q0249 Effective Date:

June 24, 2021

Q0249 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Actemra billing and coding information.
Actemra patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
ACTEMRA prescribing information can be found at the link below:
Information regarding ACTEMRA’s side effects can be found at MedlinePlus